Aridis Pharmaceuticals Said On March 20, Got Written Notice From Medimmune That It Has Terminated License Agreement Dated As Of July 12, 2021 Effective March 30; As Result Of Termination Notice, On-going Ar-320-003 Phase 3 Clinical Study Must Be Put On Hold
Charles Gross